Genitourinary Syndrome of Menopause: Prevalence and Predictors

Clin Obstet Gynecol. 2024 Mar 1;67(1):27-42. doi: 10.1097/GRF.0000000000000847. Epub 2023 Dec 21.

Abstract

The genitourinary syndrome of menopause (GSM) has been proposed as a diagnosis by a consensus of clinicians and investigators. Our purpose for this paper is to review extant evidence about: 1) the breadth of symptoms and symptom clusters as related to the syndrome; 2) the prevalence of GSM (includes vulvar and vaginal atrophy); 3) factors that are associated with, predict, or explain the syndrome; and 4) what should be pursued for expanding meaningful evidence. Within recent literature, we found a wide range of prevalence estimates, likely a function of the differing populations studied, study design, and methods of data collection. Factors related to the prevalence of GSM included age and aging; reproductive aging stage; hormones, especially estrogen; and culture and language. We recommend further specification of diagnostic criteria for GSM; clarification of urinary symptoms in GSM; use of longitudinal study designs; validation of GSM-related measures; exploration of cultural equivalence of GSM measures; and assessing biases in completed research.

Publication types

  • Review

MeSH terms

  • Atrophy
  • Estrogens
  • Female
  • Humans
  • Longitudinal Studies
  • Menopause*
  • Prevalence
  • Syndrome
  • Vagina* / pathology

Substances

  • Estrogens